Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28199419 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM2EPHX2MDM4 | |
| SCHEMBL5843620 | 0.88 | KMT2A (0.47) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL5844257 | 0.88 | CASP3 (0.45) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL5842440 | 0.87 | MDM2 (0.49) | CASP3KMT2AMDM2EPHX2MDM4 | |
| SCHEMBL30355283 | 0.87 | CASP3 (0.45) | CASP3KMT2AEPHX2 | |
| SCHEMBL14371453 | 0.84 | KMT2A (0.52) | CASP3KMT2AMDM2EPHX2MDM4 | |
| SCHEMBL13165082 | 0.84 | KMT2A (0.47) | CASP3KMT2AMDM2EPHX2 | |
| SCHEMBL8130019 | 0.84 | KMT2A (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31720042 | 0.84 | KMT2A (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29401461 | 0.84 | KMT2A (0.54) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | CASP3 461/4885KMT2A 3983/4885MDM2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.